Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : RA Capital Management
Deal Size : $50.0 million
Deal Type : Series A Financing
Details : The funding will support company's lead therapeutic approach that inhibits Gasdermin D, which has been recently discovered as a key target at the core of multiple inflammatory cell death pathways.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 27, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : RA Capital Management
Deal Size : $50.0 million
Deal Type : Series A Financing
Reset All
